(Press-News.org) WASHINGTON, D.C. (March 8 2011) -- Viruses can penetrate every part of the body, making them potentially good tools for gene therapy or drug delivery. But with our immune system primed to seek and destroy these foreign invaders, delivering therapies with viruses is currently inefficient and can pose a significant danger to patients.
Now scientists at the University of Pennsylvania have engineered a virus with potential to solve this problem. They describe the new virus today at the 55th Annual Biophysical Society Meeting in Baltimore, MD.
"We would like to find a way to avoid the immune system and maximize the dose delivered to a tumor or diseased tissue," explains professor Dennis Discher of the University of Pennsylvania. He and his colleagues have created a lentiviral vector that expresses CD47, the "marker of self" protein, on its surface. The protein gives cells a free license from macrophages, the immune system's policemen.
"This marker of self protein is found on all of our cells and tames our immune system," says Discher, senior study author. Discher explains that every cell is like a driver. A macrophage 'policeman' pulls each cell over at a traffic stop and checks its drivers license -- the marker protein. "The policeman says go on if it's valid. If not, then the macrophage eats you," he says.
By tagging CD47 with green fluorescent protein, the team confirmed that the engineered virus, which is hundreds of times smaller than human cells, was carrying the marker of self. "Assessing the expression of the protein on the surface of an individual virus has been a real biophysical challenge, addressed with a combination of single molecule fluorescence methods and atomic force microscopy," says lead author Nisha Sosale, a graduate student at the University of Pennsylvania.
In cell culture experiments in the laboratory, the engineered virus passed inspection and was eaten less frequently by macrophages. "It looks like, by engineering the viral surface, we have made the viruses look like self," says Discher.
###
This work was funded by the National Institutes of Health.
The presentation, "Reducing Immune Response Against Lentiviral Vectors: Lentiviral Vector Presentation of CD47, the 'Marker of Self'" by Nisha Sosale, Richard K. Tsai, Irena Ivanovska, and Dennis E. Discher is at 1:45 p.m. on Tuesday, March 8, 2011 in the Baltimore Convention Center, Hall C. ABSTRACT: http://tinyurl.com/4wc4o2q
MORE MEETING INFORMATION
Each year, the Biophysical Society Annual Meeting brings together more than 6,000 scientists and hosts more than 4,000 poster presentations, 200 exhibits, and more than 20 symposia. The largest meeting of its type in the world, the Biophysical Society Annual Meeting retains its small-meeting flavor through its subgroup meetings, platform sessions, social activities, and committee programs.
QUICK LINKS
Meeting Home Page:
http://www.biophysics.org/2011meeting
General Meeting Information:
http://www.biophysics.org/GeneralInfo/Overview/tabid/2062/Default.aspx
Search abstracts:
http://www.abstractsonline.com/plan/start.aspx?mkey={FEA830A5-24AD-47F3-8E61-FCA29F5FEF34}
PRESS REGISTRATION
The Biophysical Society invites credentialed journalists, freelance reporters working on assignment, and public information officers to attend its Annual Meeting for free. For more information on registering as a member of the press, please contact Ellen Weiss at eweiss@biophysics.org or 240-290-5606. Also see: http://www.biophysics.org/Registration/Press/tabid/2148/Default.aspx
ABOUT THE BIOPHYSICAL SOCIETY
The Biophysical Society, founded in 1956, is a professional, scientific society established to encourage development and dissemination of knowledge in biophysics. The society promotes growth in this expanding field through its annual meeting, monthly journal, and committee and outreach activities. Its over 9,000 members are located throughout the U.S. and the world, where they teach and conduct research in colleges, universities, laboratories, government agencies, and industry. For more information on the society or the 2011 Annual Meeting, visit www.biophysics.org
END
WASHINGTON, D.C. (March 8, 2011) -- Scientists in Israel and California have developed an instrument for rapidly analyzing molecular interactions that take place viruses and the cells they infect. By helping to identify interactions between proteins made by viruses like HIV and hepatitis and proteins made by the human cells these viruses infect, the device may help scientists develop new ways of disrupting these interactions and find new drugs for treating those infections.
According to Doron Gerber, a professor at Bar Ilan University in Ramat Gan, the PING system (Protein ...
It's all too familiar: researchers announce the discovery of a new drug that eradicates disease in animals. Then, a few years later, the drug bombs in human trials. In the latest issue of the journal PLoS Medicine, ethics experts Jonathan Kimmelman, associate professor at McGill's Biomedical Ethics Unit and Department of Social Studies of Medicine, and Alex John London, associate professor of philosophy at Carnegie Mellon University, argue that this pattern of boom and bust may be related to the way researchers predict outcomes of their work in early stages of drug development.
"We ...
Economic growth in India has no automatic connection to reducing undernutrition in Indian children and so further reductions in the prevalence of childhood undernutrition are likely to depend on direct investments in health and health-related programs. These are the conclusions of a large study by researchers at the Schools of Public Health at University of Michigan and Harvard University, that is published in this week's PLoS Medicine.
Malavika Subramanyam, S V Subramanian and colleagues collected data from the National Family Health Surveys conducted in India in 1992-93 ...
In this week's PLoS Medicine, Jonathan Kimmelman from McGill University in Montreal, Canada and Alex London from Carnegie Mellon University in Pittsburgh, USA argue that ethical reviewers and decision-makers pay insufficient attention to threats to validity in pre-clinical studies and consult too narrow a set of evidence. They propose a better way for ethical and scientific decision makers to assess early phase studies: first, to attend to reporting and methodological quality in preclinical experiments that support claims of internal, construct, and external validity; and ...
WASHINGTON, DC, March 3, 2011 — Communication technologies that help people stay connected to the workplace are often seen as solutions to balancing work and family life. However, a new study in the March issue of the Journal of Health and Social Behavior suggests there may be a "dark side" to the use of these technologies for workers' health—and these effects seem to differ for women and men.
Using data from a national survey of American workers, University of Toronto researchers asked study participants how often they were contacted outside the workplace by phone, e-mail, ...
Hidden financial conflicts-of-interest are sneaking into published drug research through the back door, warns an international team of investigators, led by researchers from the Jewish General Hospital's Lady Davis Institute for Medical Research and McGill University in Montreal.
More and more, policy decisions and what medications doctors prescribe for their patients are being driven by large "studies of studies," called meta-analyses, which statistically combine results from many individual drug trials.
Led by Dr. Brett Thombs and McGill graduate student Michelle ...
In a study that included more than 120,000 adults who were treated for trauma, 16 percent of these patients died within 3 years of their injury, compared to an expected population mortality rate of about 6 percent, according to a study in the March 9 issue of JAMA. The researchers also found that trauma patients who were discharged to a skilled nursing facility had a significantly increased risk of death compared with patients discharged home without assistance.
Trauma can lead to significant illness or death. "To date, there have been few large studies evaluating long-term ...
Information concerning funding and author conflicts of interest disclosed in the original reports of randomized controlled trials is rarely disclosed when these data are combined in meta-analyses, according to an article in the March 9 issue of JAMA.
"Conflicts of interest (COIs) related to the funding of biomedical research by pharmaceutical companies and financial relationships between researchers and pharmaceutical companies have come under increased scrutiny in recent years. COIs may influence the framing of research questions, study design, data analysis, interpretation ...
Study participants who viewed a brief hands-only cardiopulmonary resuscitation (CPR) video were more likely to attempt CPR, and perform better quality CPR in an emergency than participants who did not view the short videos, according to research reported in Circulation: Cardiovascular Quality and Outcomes.
Each year, almost 300,000 people suffer out-of-hospital cardiac arrests in the United States. Survival rates from these events tend to be extremely low. However, research has shown that bystander CPR can double — even triple — survival from out-of-hospital cardiac ...
Participants in the first hospital-initiated, low-intensity collaborative care program to treat depression in heart patients showed significant improvements in their depression, anxiety and emotional quality of life after 6 and 12 weeks, researchers report in Circulation: Cardiovascular Quality and Outcomes, an American Heart Association journal.
Depression is a common condition in cardiovascular disease (CVD) patients which can result in poor prognosis and quality of life.
Collaborative care depression management programs use a non-physician care manager to coordinate ...
